The condition strikes quickly and can lead to tissue failure, organ damage, and death.
Saudi Arabia today reported two more MERS-Cov cases in different cities, after a weekend with no new cases.
An Austrian pharmaceutical company today reported promising findings from a phase 1 study of its candidate chikungunya vaccine. The vaccine, which uses a standard measles vaccine vector, induced a significant neutralizing immune response and appeared to be safe, according to a press release from the Vienna-based company, Themis Bioscience.
